San Diego, CA—Orphagen Pharmaceutical formally announced last August 12, 2010 that the National Cancer Institute (NCI) has awarded it a Phase I Small Business Innovative Research (SBIR) grant, amounting to $520,000 for over two years, for the development of new drugs for the treatment of adrenocortical and prostate cancers.
In a statement made by Scott Thacher, Ph.D., CEO and founder of Orphagen, he said that the company has had a long-term interest in developing a new class of therapeutic small molecules intended for the treatment of endocrine conditions such as adrenocortial and prostate cancers.
The study is expected to develop and demonstrate how Orphagen Pharmaceutical’s proprietary small molecules are effective in physiological targets that have the capacity to enhance therapy for the abovementioned diseases.
Globally, several thousands of individuals are suffering from adrenocortical cancer. On the other hand, there are around 30,000 deaths occurring each year in the United States due to prostate cancer.
Orphagen Pharmaceutical, as cited in CheckOrphan web site